REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

Form 424B5 REGENXBIO Inc.

Fri, 17 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26785273.html

Fri, 17 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26785273.html